Decrease in NADPH-cytochrome P450 reductase activity of the human heart, liver and lungs in the presence of alpha-lipoic acid

Annals of Nutrition and Metabolism

Volumn 50, Issue 2, 2006, Pages 121-125

  Dudka, Jaroslaw ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Lipoic acid; Human heart; Liver; Lung; NADPH cytochrome P450 reductase

Indexed keywords

CYTOCHROME C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; THIOCTIC ACID;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; HEART; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER; LUNG; MALE; MICROSOME; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; ANTIOXIDANTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; LIVER; LUNG; MALE; MICROSOMES, LIVER; MYOCARDIUM; NADPH-FERRIHEMOPROTEIN REDUCTASE; ORGAN SPECIFICITY; PARAQUAT; THIOCTIC ACID;

EID: 33644645677     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090632     Document Type: Article

References (31)

1. Berlin V, Haseltine WA: Production of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J Biol Chem 1981;256:4747-4756.
2. De Gray JA, Rao DN, Mason RP: Reduction of paraquat and related bipyridylium compounds to free radical metabolites by rat hepatocytes. Arch Biochem Biophys 1991;289:145-152.
3. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ: Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 1995;72:1144-1150.
4. Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR: Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res 2004;64:736-742.
5. Moulder JE, Rockwell S: Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-341.
6. Kennedy KA: Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 1987;2:181-194.
7. Walton MI, Wolf CR, Workman P: The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 1992;44:251-259.
8. Elwell JH, Siim BG, Evans JW Brown JM: Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol 1997;54:249-257.
9. Ames BN: Delaying the mitochondrial decay of aging. Ann NY Acad Sci 2004;1019:406-411.
10. Dudka J, Burdan F, Korobowicz A, Klepacz R, Korobowicz E: Human skeletal muscle lactate dehydrogenase activity in the presence of some alcohol dehydrogenase inhibitors. Basic Clin Pharmacol Toxicol 2004;95:38-42.
11. Dudka J, Jodynis-Liebert J, Korobowicz E, Burdan F, Korobowicz A, Szumilo J, Tokarska E, Klepacz R, Murias M: Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol - an in vitro study. Basic Clin Pharmacol Toxicol 2005;97:74-79.
12. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A: Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 1996;31:145-169.
13. Perez-Reyes E, Kalyanaraman B, Mason RP: The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes. Mol Pharmacol 1980;17:239-244.
14. Chapman DE, Holbrook DJ, Chaney SG, Hall IH, Lee KH: In vitro inhibition of mouse hepatic mixed-function oxidase enzymes by helenalin and alantolactone. Biochem Pharmacol 1989;38:3913-3923.
15. Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC: Role of NADPH: Cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. Cancer Res 1984;44:5638-5643.
16. Bartoszek A, Wolf CR: Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase. Biochem Pharmacol 1992;43:1449-1457.
17. Bartoszek A: Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase: overview of its biological and biochemical effects. Acta Biochim Pol 2002;49:323-331.
18. Griffith OW, Stuehr DJ: Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 1995;57:707-736.
19. Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, Heng HH, Rommens JM, Scherer SW, Rosenblatt DS, Gravel RA: Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 1998;95:3059-3064.
20. Paine MJ, Garner AP, Powell D, Sibbald J, Sales M, Pratt N, Smith T, Tew DG, Wolf CR: Cloning and characterization of a novel human dual flavin reductase. J Biol Chem 2000;275:1471-1478.
21. Yelinova V, Weiner L, Slepneva I, Levina A: Reversible modification of cysteine residues of NADPH-cytochrome P-450 reductase. Biochem Biophys Res Commun 1993;193:1044-1048.
22. Slepneva I, Sergeeva SV, Khramtsov VV: Reversible inhibition of NADPH-cytochrome P450 reductase by α-lipoic acid. Biochem Biophys Res Commun 1995;214:1246-1253.
23. Rosenfeldt F, Miller F, Nagley P, Hadj A, Marasco S, Quick D, Sheeran F, Wowk M, Pepe S: Response of the senescent heart to stress: clinical therapeutic strategies and quest for mitochondrial predictors of biological age. Ann NY Acad Sci 2004;1019:78-84.
24. Zaporozhchenko BS, Shishlov VI: Functional state of the liver in patients with an acute destructive pancreatitis in the early postoperative period. Klin Khir 2005;1:29-31.
25. Shila S, Subathra M, Devi MA, Panneerselvam C: Arsenic intoxication-induced reduction of glutathione level and of the activity of related enzymes in rat brain regions: reversal by DL: alpha-lipoic acid. Arch Toxicol 2005;3:140-146.
26. Hall PM, Stupans, Burgess W, Birkett DJ, McManus ME: Immunohistochemical localization of NADPH-cytochrome P450 reductase in human tissues. Carcinogenesis 1989;10:521-530.
27. Wu L, Gu J, Cui H, Zhang QY, Behr M, Fang C, Weng Y, Kluetzman K, Swiatek PJ, Yang W, Kaminsky L, Ding X: Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 2005;312:35-43.
28. Balachandar AV, Malarkodi KP, Varalakshmi P: Protective role of DLalpha-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum Exp Toxicol 2003;22:249-254.
29. Al-Majed AA, Gdo AM, Al-Shabanah OA, Mansour MA: Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin. Pharmacol Res 2002;46:499-503.
30. Malarkodi KP, Sivaprasad R, Varalakshmi P: Effect of lipoic acid on the oxidoreductive status of red blood cells in rats subject to oxidative stress by chronic administration of adriamycin. Hum Exp Toxicol 2004;23:129-135.
31. Malarkodi KP, Balachandar AV, Varalakshmi P: Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney. Mol Cell Biochem 2003;247:9-13.